BackPurple Biotech Overview

Purple Biotech Receivables

Purple Biotech's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Purple Biotech Receivables History

Loading

Purple Biotech vs. peers: Receivables Comparison

Loading

Purple Biotech Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Purple Biotech (PPBT) FAQ

Purple Biotech (PPBT) currently reports a receivables of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Purple Biotech's receivables history and peer comparisons.

Purple Biotech's receivables changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Purple Biotech reported $0 in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Purple Biotech, and consider following PPBT for alerts when major investors trade the stock.

Purple Biotech is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PPBT with unrelated industries.